Ligand Reports First Quarter 2019 Financial Results
Ligand Completes Enrollment of Phase 1 Clinical Trial of Captisol-enabled Iohexol
Ligand to Report First Quarter 2019 Results on May 2nd
Ligand to Receive Milestone and Royalties as Result of FDA Approval of Sage Therapeutics’ ZULRESSO™ (brexanolone) Injection
Ligand to Participate in Four Upcoming Investor Conferences
Ligand Provides Highlights from Today’s Analyst Day Event
Ligand Sells Promacta Assets and Royalty for $827 Million
Reminder: Ligand to Host Analyst Day on March 12th in New York City
Ligand Reports Fourth Quarter and Full Year 2018 Financial Results
